Show simple item record

dc.contributor.authorSánchez-Guijo, Fermín
dc.contributor.authorGarcía-Olmo, Damián
dc.contributor.authorPrósper, Felipe
dc.contributor.authorMartínez, Salvador
dc.contributor.authorZapata, Agustín
dc.contributor.authorFernández-Avilés, Francisco
dc.contributor.authorToledo-Aral, Juan José
dc.contributor.authorTorres, Miguel 
dc.contributor.authorFariñas, Isabel
dc.contributor.authorBadimón, Lina
dc.contributor.authorLabandeira-García, José Luis
dc.contributor.authorGarcía-Sancho, Javier
dc.contributor.authorMoraleda, José M
dc.date.accessioned2020-03-09T14:23:03Z
dc.date.available2020-03-09T14:23:03Z
dc.date.issued2020-01
dc.identifier.citationCytotherapy. 2020; 22(1):1-5es_ES
dc.identifier.issn14653249es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9248
dc.description.abstractIn the current article we summarize the 15-year experience of the Spanish Cell Therapy Network (TerCel), a successful collaborative public initiative funded by the Spanish government for the support of nationwide translational research in this important area. Thirty-two research groups organized in three programs devoted to cardiovascular, neurodegenerative and immune-inflammatory diseases, respectively, currently form the network. Each program has three working packages focused on basic science, pre-clinical studies and clinical application. TerCel has contributed during this period to boost the translational research in cell therapy in Spain, setting up a network of Good Manufacturing Practice-certified cell manufacturing facilities- and increasing the number of translational research projects, publications, patents and clinical trials of the participating groups, especially those in collaboration. TerCel pays particular attention to the public-private collaboration, which, for instance, has led to the development of the first allogeneic cell therapy product approved by the European Medicines Agency, Darvadstrocel. The current collaborative work is focused on the development of multicenter phase 2 and 3 trials that could translate these therapies to clinical practice for the benefit of patients.es_ES
dc.description.sponsorshipThis manuscript has been supported by the Instituto de Salud Carlos III (ISCIII) through the project“RD16/0011/0001: Red de TerapiaCelular”, from the sub-program RETICS, integrated in the“Plan Estatalde I+D+I 2013-2016”and co-financed by the European RegionalDevelopment Fund“A way to make Europe”. D.G.O. has been an Advi-sory Board member of TiGenix SAU, and received consulting feesfrom Takeda. He also holds patents 10157355957US and US11/167061 related to Darvadstrocel.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectcell therapyes_ES
dc.subjectregenerative medicinees_ES
dc.subjectresearch networkes_ES
dc.subjectstem cellses_ES
dc.subjecttranslational medicinees_ES
dc.titleSpanish Cell Therapy Network (TerCel): 15 years of successful collaborative translational researches_ES
dc.typeArtículoes_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID31866320es_ES
dc.format.volume22es_ES
dc.format.number1es_ES
dc.format.page1-5es_ES
dc.identifier.doi10.1016/j.jcyt.2019.11.001es_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1477-2566es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.jcyt.2019.11.001es_ES
dc.identifier.journalCytotherapyes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Control Genético del Desarrollo y Regeneración de Órganoses_ES
dc.repisalud.institucionCNICes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16/0011/0001es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional